Catalog No.S1905 Synonyms: UK-48340
Molecular Weight(MW): 408.88
Amlodipine is a long-acting calcium channel blocker, used to lower blood pressure and prevent chest pain.
Purity & Quality Control
Choose Selective Calcium Channel Inhibitors
|Description||Amlodipine is a long-acting calcium channel blocker, used to lower blood pressure and prevent chest pain.|
Amlodipine causes a dose-dependent increase in nitrite production. Amlodipine also increases nitrite production in large coronary arteries and in aorta.  Amlodipine is attributed to distinct membrane physico-chemical interactions. Amlodipine contributes to distinct membrane biophysical interactions that lead to potent lipid antioxidant effects, independent of calcium channel modulation.  Amlodipine increases plaque smooth muscle cell content (P<0.05), whereas atenolol decreases plaque inflammation.  Amlodipine attenuates intracellular neuronal Ca2+ increases elicited by KCl depolarization but does not affect Ca2+ changes triggered by N-methyl-D-aspartate receptor activation. Amlodipine also inhibits free radical-induced damage to lipid constituents of the membrane in a dose-dependent manner, independent of Ca2+ channel modulation. 
|In vivo||Amlodipine results in regression of cardiovascular hypertrophy and amelioration of endothelial dysfunction in spontaneously hypertensive rats.  Amlodipine significantly reduces aortic hypertrophy, endothelial dysfunction, LOX-1 expression, aortic O(2)(-) and ONOO(-) production, and plasma free 8-F(2)alpha-isoprostane levels in Ang II-infused rats. Amlodipine has antihypertensive and antioxidant activity in vivo, which effectively inhibits many of the oxidative stress-dependent mechanisms involved in Ang II-mediated cardiovascular injury. |
-  Zhang X, et al. Circulation, 1998, 97(6), 576-580.
-  Mason RP, et al. J Mol Cell Cardiol, 1999, 31(1), 275-281.
-  Nussberger J, et al. Hypertension, 2008, 51(5), 1306-1311.
|In vitro||DMSO||82 mg/mL (200.54 mM)|
|Ethanol||82 mg/mL (200.54 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03226275||Completed||Healthy||Merck KGaA||August 9 2017||Phase 1|
|NCT02969265||Withdrawn||Hypertension||Takeda||May 9 2017||Phase 3|
|NCT02742467||Completed||Hypertension||University of Abuja|Imperial College London|University of Cape Town|Hôpital Edouard Herriot|University of Nairobi|University College Hospital Ibadan|Hospital General De Douala|Mulago Hospital Uganda||June 7 2017||Phase 4|
|NCT03461081||Completed||Hypertension With Hyperlipidemia||Jeil Pharmaceutical Co. Ltd.||May 7 2017||Phase 1|
|NCT03210532||Completed||Hypertension|Dyslipidemia||Daewon Pharmaceutical Co. Ltd.||October 7 2016||Phase 3|
|NCT02896621||Completed||Hypertension|Sleep Apnea||Hospital de Clinicas de Porto Alegre||December 7 2014||Phase 3|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.